BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20406065)

  • 1. Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease?
    Canbakan B; Senturk H; Canbakan M; Toptas T; Tabak O; Balci H; Olgac V; Ozbay G
    Biomark Med; 2010 Apr; 4(2):205-14. PubMed ID: 20406065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical and histological features of non-alcoholic fatty liver disease].
    Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.
    Mofrad P; Contos MJ; Haque M; Sargeant C; Fisher RA; Luketic VA; Sterling RK; Shiffman ML; Stravitz RT; Sanyal AJ
    Hepatology; 2003 Jun; 37(6):1286-92. PubMed ID: 12774006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis markers in liver biopsy of nonalcoholic steatohepatitis in pediatric patients.
    Valva P; De Matteo E; Galoppo M; Pedreira A; Giacove G; Lezama C; Marco I; Galoppo MC; Preciado MV
    Hum Pathol; 2008 Dec; 39(12):1816-22. PubMed ID: 18715620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.
    Wieckowska A; Zein NN; Yerian LM; Lopez AR; McCullough AJ; Feldstein AE
    Hepatology; 2006 Jul; 44(1):27-33. PubMed ID: 16799979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
    Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S
    Hepatology; 2008 Sep; 48(3):792-8. PubMed ID: 18752331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of blood oxidative stress-related parameters in alcoholic liver disease and non-alcoholic fatty liver disease.
    Das KS; Balakrishnan V; Mukherjee S; Vasudevan DM
    Scand J Clin Lab Invest; 2008; 68(4):323-34. PubMed ID: 18609067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?
    McPherson S; Anstee QM; Henderson E; Day CP; Burt AD
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):652-8. PubMed ID: 23325287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes.
    Rodríguez-Hernández H; Gonzalez JL; Márquez-Ramirez MD; Flores-Hernandez M; Rodríguez-Morán M; Guerrero-Romero F
    Eur J Gastroenterol Hepatol; 2008 May; 20(5):399-403. PubMed ID: 18403941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.
    Tsutsui M; Tanaka N; Kawakubo M; Sheena Y; Horiuchi A; Komatsu M; Nagaya T; Joshita S; Umemura T; Ichijo T; Matsumoto A; Yoshizawa K; Aoyama T; Tanaka E; Sano K
    J Clin Gastroenterol; 2010 Jul; 44(6):440-7. PubMed ID: 20104187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chan AW; Choi PC; Chim AM; Chu S; Chan FK; Sung JJ; Chan HL
    Aliment Pharmacol Ther; 2009 Feb; 29(4):387-96. PubMed ID: 19035982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women.
    Kunde SS; Lazenby AJ; Clements RH; Abrams GA
    Hepatology; 2005 Sep; 42(3):650-6. PubMed ID: 16037946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD).
    Madan K; Bhardwaj P; Thareja S; Gupta SD; Saraya A
    J Clin Gastroenterol; 2006; 40(10):930-5. PubMed ID: 17063114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C infection?
    Sanai FM; Benmousa A; Al-Hussaini H; Ashraf S; Alhafi O; Abdo AA; Alameri HF; Akbar HO; Bzeizi KI
    Liver Int; 2008 Aug; 28(7):1011-8. PubMed ID: 18384520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats.
    Zhao JS; Zhu FS; Liu S; Yang CQ; Chen XM
    Chin Med J (Engl); 2012 Jul; 125(13):2316-21. PubMed ID: 22882855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values.
    Amarapurkar DN; Patel ND
    Trop Gastroenterol; 2004; 25(3):130-4. PubMed ID: 15682660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients.
    Ribeiro PS; Cortez-Pinto H; Solá S; Castro RE; Ramalho RM; Baptista A; Moura MC; Camilo ME; Rodrigues CM
    Am J Gastroenterol; 2004 Sep; 99(9):1708-17. PubMed ID: 15330907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk.
    Tahan V; Canbakan B; Balci H; Dane F; Akin H; Can G; Hatemi I; Olgac V; Sonsuz A; Ozbay G; Yurdakul I; Senturk H
    Hepatogastroenterology; 2008; 55(85):1433-8. PubMed ID: 18795706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Investigation of oxidative stress and antioxidant defense in patients with hepatitis B virus infection and the effect of interferon-alpha plus lamivudine combination therapy on oxidative stress].
    Acar A; Görenek L; Aydin A; Eyigün CP; Eken A; Sayal A; Pahsa A
    Mikrobiyol Bul; 2009 Jul; 43(3):411-23. PubMed ID: 19795616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.